5Ficheux H, Domagala F. Pharmacokinetics of tenatoprazole, a novel proton pump inhibitor, in healthy male Caucasian volunteers [J]. Gastroenterology, 2003, 124(4): A231.
6Shin JM, Homerin M, Domagala F, et al. Characterization of the inhibitory activity of tenatoprazole on the gastric H+/K+- ATPase in vitro and in vivo [J]. Biochem Pharmacol, 2006, 71(6): 837-849.
7Galmiche JP, Sacher-Huvelin S, Bruley des Varannes S, et al. A comparative study of the early effects of tenatoprazole 40 mg and esomeprazole 40 mg on intragastric pH in healthy volunteers [J]. Aliment Pharmacol Ther, 2005, 21(5): 575- 582.
8Galmiche JP, Bruley des Varannes S, Ducrott6 P, et al. Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in healthy volunteers [J]. Aliment Pharmacol Ther, 2004, 19(6): 655-662.
9Hunt RH, Armstrong D, James C, et al. Effect on intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esomeprazole on the durationof acid suppression in healthy male volunteers [J]. Am J Gastroenterol, 2005, 100(9): 1949-1956.
10Hunt Rtt, Armstrong D. Yaghoobi M, et al. The pharmacodynamics and pharmacokinetics of S-tenatoprazole- Na 30 rag, 60 mg and 90 mg vs. esomeprazole 40 mg in healthy male subjects [J]. Aliment Pharmacol Ther, 2010, 31 (6): 648-657.
